These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7359247)

  • 1. Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient.
    Chiba K; Ishizaki T; Miura H; Minagawa K
    J Pediatr; 1980 Mar; 96(3 Pt 1):479-84. PubMed ID: 7359247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient.
    Miura H; Minagawa K
    Folia Psychiatr Neurol Jpn; 1980; 34(3):295. PubMed ID: 7216015
    [No Abstract]   [Full Text] [Related]  

  • 3. Apparent Michaelis-Menten kinetic parameters of phenytoin in pediatric patients.
    Chiba K; Ishizaki T; Miura H; Minagawa K
    Pediatr Pharmacol (New York); 1980; 1(2):171-80. PubMed ID: 7346739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of bioavailability on the calculated Michaelis-Menten parameters of phenytoin in children.
    Koren G; Brand N; MacLeod SM
    Ther Drug Monit; 1984; 6(1):11-4. PubMed ID: 6710554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients.
    Bauer LA; Blouin RA
    Clin Pharmacokinet; 1983; 8(6):545-9. PubMed ID: 6653035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenytoin dosage requirements and pharmacokinetic variables.
    Taylor JW; Murphy MJ; Berg MJ; Perry PJ; Lyon LW; Ludden TM
    Clin Pharm; 1983; 2(3):253-7. PubMed ID: 6883953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenytoin age-dose-concentration relationship in children.
    Suzuki Y; Mimaki T; Cox S; Koepke J; Hayes J; Walson PD
    Ther Drug Monit; 1994 Apr; 16(2):145-50. PubMed ID: 8009561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diphenylhydantoin elimination kinetics in overdosed children.
    Garrettson LK; Jusko WJ
    Clin Pharmacol Ther; 1975 Apr; 17(4):481-91. PubMed ID: 1122689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma concentrations of 5-(4-hydroxyphenyl)-5-phenylhydantoin in phenytoin-treated patients.
    Hoppel C; Garle M; Rane A; Sjöqvist F
    Clin Pharmacol Ther; 1977 Mar; 21(3):294-300. PubMed ID: 837648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diphenylhydantoin: efficacy, toxicity, and dose-serum level relationships in children.
    Borofsky LG; Louis S; Kutt H; Roginsky M
    J Pediatr; 1972 Nov; 81(5):995-1002. PubMed ID: 5086732
    [No Abstract]   [Full Text] [Related]  

  • 11. Individualization of phenytoin dosage regimens.
    Ludden TM; Allen JP; Valutsky WA; Vicuna AV; Nappi JM; Hoffman SF; Wallace JE; Lalka D; McNay JL
    Clin Pharmacol Ther; 1977 Mar; 21(3):287-93. PubMed ID: 837647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenytoin dosage adjustment in Saudi epileptics: utilization of steady-state pharmacokinetic parameters.
    Abduljabbar M; Al-Khamis K; Ogunniyi A; Daif AK; Al-Yamani M
    Eur J Neurol; 1999 May; 6(3):331-4. PubMed ID: 10210914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenytoin--allopurinol interaction: Michaelis--Menten kinetic parameters of phenytoin with and without allopurinol in a child with Lesch--Nyhan syndrome.
    Yokochi K; Yokochi A; Chiba K; Ishizaki T
    Ther Drug Monit; 1982; 4(4):353-7. PubMed ID: 7157458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Blood levels of phenytoin. Pharmacokinetics and individualization of dosages in controlled children with crises and with persistence of crises].
    García-Márquez F; Rodríguez-Blancas MC; Juárez-Olguín H; Díaz-López B; Ruiz-Chávez J
    Bol Med Hosp Infant Mex; 1990 Oct; 47(10):682-8. PubMed ID: 2278644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three Michaelis-Menten pharmacokinetic dosing methods compared with physician dosing of phenytoin in an outpatient neurology practice.
    Spruill WJ; Wade WE; Cobb HH; Akbari S
    Pharmacotherapy; 2001 Nov; 21(11):1407-14. PubMed ID: 11714214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum theophylline and phenytoin levels: can we afford to do them? Can we afford not to?
    Kuhn G
    Ann Emerg Med; 1986 Mar; 15(3):344-8. PubMed ID: 3946882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A complex pattern of disposition of phenytoin in severe intoxication.
    Pruitt AW; Zwiren GT; Patterson JH; Dayton PG; Cook CE; Wall ME
    Clin Pharmacol Ther; 1975 Jul; 18(1):112-20. PubMed ID: 238781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug interaction: diazoxide and diphenylhydantoin.
    Roe TF; Podosin RL; Blaskovics ME
    J Pediatr; 1975 Sep; 87(3):480-4. PubMed ID: 1165531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of phenytoin in South African black patients.
    Miller R; Rheeders M; Klein C; Suchet I
    S Afr Med J; 1987 Aug; 72(3):188-90. PubMed ID: 3603312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualizing phenytoin dosage regimens using a programmable calculator.
    Ng PK
    Am J Hosp Pharm; 1980 Apr; 37(4):529-33. PubMed ID: 7377216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.